Resumen de: US2023090515A1

The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.

Resumen de: US2023087405A1

The present invention provides nanoparticles comprising a) a micelle comprising an amphiphilic polymer with a number average molecular weight (Mn) of 20,000 g/mol or less, and b) at least one peptide comprising at least one T cell epitope. The present invention further provides pharmaceutical compositions comprising these nanoparticles and the use of the compositions for suppressing specific immune responses.

Resumen de: US2023092662A1

The present disclosure relates to cisplatin nanoparticle compositions and a method for the preparation thereof. A phospholipid complex of cisplatin is prepared for increased absorption, followed by the phospholipid complex is converted into lipid nanoparticles by choosing appropriate solvents, incorporation of lipids, stabilizers under optimum conditions of agitation, temperature and solvent evaporated under reduced pressure. The incorporation of lipids and stabilizers for the formulation of nanoparticles based cisplatin leads to the formation of micelles and mixed micelles that enhance the cisplatin absorption into systemic circulation because of the nano size and by lymphatic transport. The nanoparticle based composition of cisplatin that is administered orally. It is safe, effective, convenient and affordable to the patient.

Resumen de: US2023092673A1

Presented herein, in certain aspects, are cell-free therapeutic composition derived from human amniotic fluid (HAF) and uses thereof for the prevention and treatment of selected diseases and disorders.

Resumen de: US2023092885A1

A method of inducing cell death in a subject includes administering to the subject a plurality of cell targeted nanobubbles that are internalized by the target cell and insonating nanobubbles internalized into the target cell with ultrasound energy effective to promote inertial cavitation of the internalized nanobubbles and apoptosis and/or necrosis of the target cell.

Resumen de: US2023093138A1

The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.

Resumen de: US2023087306A1

The present disclosure relates generally to unconjugated PLGA nanoparticles in the treatment of Alzheimer's Disease. The present disclosure provides a method of treating a subject having Alzheimer's Disease or a tauopathy or suspected of having Alzheimer's Disease or a tauopathy, the method includes administering a therapeutically effective amount of poly(D,L-lactide-co-glycolide) (PLGA) to the subject.

Resumen de: US2023087420A1

The disclosure provides a method of forming carbon dots, including admixing carbon powder with sulfuric acid and nitric acid and heating the carbon powder mixture to reflux to oxidize the carbon powder. The method further includes isolating and purifying the carbon dots. The disclosure further provides applications of the carbon dots for diagnostic analysis (such as bone analysis), fibrillation inhibition, and drug delivery.

Resumen de: US2023087975A1

A water-soluble conjugated polymer for photothermal therapy, a polymerized monomer thereof, a preparation method therefor, and application thereof. The water-soluble conjugated polymer has good solubility in an aqueous solution, has excellent biocompatibility, does not need to be subjected to coating treatment, can be directly used for photothermal therapy, is easy to use, has a nanometer size, and can enter cells easily. Polar groups are contained in side chains, and the water-soluble conjugated polymer is capable of targeting, can locate intracellular organelles, has excellent photostability and chemical properties as well as high photothermal conversion efficiency, can achieve photothermal therapy of near-infrared region I or II, with high treatment efficiency and few side effects. In the preparation method for the water-soluble conjugated polymer, raw materials can be easily obtained, synthesis conditions are mild, and the purification is convenient. The preparation method is simple, can be easily implemented, and has a great application prospect.

Resumen de: US2023090223A1

A nanoparticle comprising chemically modified heparin, wherein the heparin has been chemically modified by attaching hydrophobic moieties to functional groups of the heparin, said functional groups being selected from hydroxy groups and carboxy groups, for use in the treatment or diagnosis of a brain disorder.

Resumen de: US2023085710A1

The present invention relates to compositions comprising polyinosinic (poly(I))-polycytidylic acid poly(C) molecules, or a salt and/or solvate thereof, comprising double-stranded polyribonucleotides. The present invention further relates to compositions wherein the disclosed respective poly(I) and poly(C) single-stranded molecules are annealed to thereby form double-stranded poly(I:C) molecules.

Resumen de: US2023086030A1

Disclosed are a lymphoma cell-specific drug delivery system for the prevention or treatment of lymphoma and a production method therefor. The lymphoma cell-specific drug delivery system may be delivered into lymphoma cells in an improved manner compared to conventional single-target drug delivery systems, and is applicable to the delivery of various therapeutic drugs for the treatment of lymphoma through the application of a wide range of drugs and the same antibody functionalization strategy on the surface of different types of nanoparticles. In addition, the drug delivery system may be introduced into lymphoma as well as other cancer types by adjusting the type and mixing ratio of antibody, and may propose a method of introducing polymeric nucleic acid drugs having superior physiological stability and drug efficacy compared to conventional monomeric nucleic acid drugs, thereby enabling effective drug treatment of lymphoma which is highly resistant to intracellular drug delivery.

Resumen de: US2023086363A1

Fluorescent bimetallic nanocomposites (M1@M2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) are prepared by reducing silver nitrate (AgNO3) on gold nanoparticles (AuNPs) and platinum nanoparticles (PtNPs) using sodium borohydride (NaBH4) at alkaline pH=11, in the presence of a lysozyme that acts as a template, and in the presence of a capping and stabilizing agent. The biocompatible bimetallic nanocomposites (M1@M2-NCs) have promising multifunctional applications (cell imaging, bio-sensing, therapeutics) observed by both in vitro as well as in vivo experiments. The fluorescent bimetallic nanocomposites (M1@M2-NCs) of silver-gold (Ag@Au-NC) and silver-platinum (Ag@Pt-NC) may be useful as an alternative nanomedicine in cancer theranostics applications.

Resumen de: US2023086800A1

Anti-PD-1/PD-L1 antibody conjugated nanoparticles and methods of treating cancer, including without limitation hepatocellular carcinoma, are provided. The conjugates comprise antibodies, e.g. antibody F(ab) fragments, covalently linked to nanopartides. The antibody conjugated nanoparticles provide high tumor-specific delivery by extending circulation time of the antibodies by increasing their geometry and removing the Fc portion, and minimizing off-target distribution and toxicity. In some embodiments the antibody conjugated nanoparticlesprovide for increased therapeutic efficacy, e.g. in decreased tumor growth, relative to unconjugated antibody, or relative to unconjugated F(ab) fragments of an antibody.

Resumen de: US2023087023A1

A nano small peptide FH and its use in preparation of drugs for treating and preventing fundus vascular diseases are provided. The artificially synthesized nano small peptide has a molecular formula of X-FFVLK-KQKRPRH (SEQ ID NO: 1), wherein the X is C12, C14, C16, or C18. The nano small peptide of the present invention can specifically select receptors to encapsulate sSema4D protein, and the concentration of sSema4D is effectively reduced, so that the sSema4D is unable to bind to any receptors, thus changing the shortcoming of few inhibitory targets of antibody drugs. The nano small peptide molecule with a simple structure can be mixed with antibody drugs without causing mutual immune reactions, so as to achieve the effect of reducing multiple pro-angiogenesis molecules.

Resumen de: US2023087061A1

A combination therapy involving different therapeutic molecules can enhance and improve the therapeutic potentials. An effective therapeutic strategy conjugates silica (SiO2) nanoparticles with, e.g., 3-glycidyloxypropyl, trimethoxysilane and azoles, e.g., 1,2,4-triazole (Tri), 3-aminotriazole (ATri), 5-aminetetrazole (Atet), imidazole (Imi). These exemplary materials—classified as SiO2-3GPS-Tri (Conj. 1), SiO2-3GPS-Atri (Conj. 2), SiO2-3GPS-Atet (Conj. 3), SiO2-3GPS-Btri (Conj. 4), and SiO2-3GPS-Imi (Conj. 5)—can amplify targeting of therepeutics for human colorectal carcinoma cells (HCT-116), enhancing anti-cancer effects.

Resumen de: US2023091673A1

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Resumen de: EP3909612A1

The disclosure relates to a composition of nanoparticles as carrier for pharmaceutically acceptable compounds, a method for the preparation of the composition and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition.

Resumen de: WO2021228800A1

The present invention relates to slow release plasminogen activator composition. The present invention also relates to the therapeutic use of said composition, in particular in thrombotic or haemorrhagic disease.

Resumen de: EP3909612A1

The disclosure relates to a composition of nanoparticles as carrier for pharmaceutically acceptable compounds, a method for the preparation of the composition and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition.

Resumen de: WO2021228832A1

The application relates to the use of loaded red blood cells (e.g. "RBCs", "red cells" or "erythrocytes") or red blood cell precursors to produce red cell extracellular vesicles (RCEVs) containing cargos, including cargos comprising biologically active ingredients. Notable red cell precursors include hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), and reticulocytes. The cargo may comprise nucleic acids, proteins, small molecules, or components of a gene editing system, including CRISPR/Cas9. The RCEVs may be used to treat of diseases and disorders including autoimmune disorders, cancers, cardiovascular diseases, gastrointestinal diseases, genetic disorders, or inflammatory diseases. The RCEVs may also be used to carry antigens and or immune modulator, for use in eliciting immune or immune tolerance responses. Also provided are methods for producing cargo loaded RCEVs (CLRCEVs) by first loading cargo into red cells and then by vesiculating the cargo loaded red cells to yield the CLRCEVs.

Resumen de: EP3909612A1

The disclosure relates to a composition of nanoparticles as carrier for pharmaceutically acceptable compounds, a method for the preparation of the composition and the use of the composition for medical purposes, in particular for immunoprophylaxis or immunotherapy. The invention also relates to a vaccine containing the composition.

Resumen de: WO2021231350A1

Microparticulate compositions and methods for delivery and pulsatile release of one or more sting agonists and/or receptors have been developed. The compositions include polymeric microdevices formed from biodegradable and biocompatible polymers or co-polymers thereof including a shell and compartment(s) or discrete regions in the compartment(s) formed by an additive process such as micromolding, three-dimensional printing and lithography. The compositions include microdevices that release individual doses of incorporated STING agonist and/or receptors at defined times, for example, in pulses up to several months after administration with essentially no leakage between releases.

Resumen de: WO2021231854A1

The disclosure features LNP compositions and systems comprising a therapeutic payload or prophylactic payload, a binding element, a tether molecule and/or an effector molecule and uses thereof. The LNP compositions or systems of the present disclosure comprise: (a) a first polynucleotide (e.g., mRNA) comprising: (1) a sequence encoding a therapeutic payload or prophylactic payload, and (2) a binding element; and (b) a second polynucleotide (e.g., mRNA) comprising a sequence encoding: (1) an effector molecule, and/or (2) a polypeptide that recognizes the binding element (a tether molecule). Such compositions or systems can: increase the level and/or activity of the therapeutic payload or prophylactic payload, e.g., increase the level, stability and/or activity of the mRNA encoding the therapeutic payload or prophylactic payload. Also disclosed herein are methods of treating a disorder, or for modulating an immune response in a subject using the disclosed LNP compositions or systems.

Resumen de: WO2021231901A1

The present invention provides, among other things, methods of encapsulating messenger RNA in lipid nanoparticles without the use of flammable solvents, and compositions produced by these methods, for mRNA delivery in therapeutic use. The present invention is, in part, based on the surprising discovery that mRNA can be encapsulated with high efficiency, without using an ethanol solvent, in the presence of an amphiphilic polymer. Thus, the present invention provides safe, cost-effective, and efficient methods of producing LNP formulations from large scale manufacturing processes as well as in low volume formulations for therapeutic applications.